Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Common cold virus originated in camels, study shows
camel
"Our current study gives us a warning sign regarding the risk of a MERS pandemic - because MERS could perhaps do what HCoV-229E did."
Scientists concerned about the potential for a MERS pandemic
 
New research suggests that one of the four human coronaviruses that cause common colds originated in camels.

The discovery has prompted fears over a potential pandemic of Middle East respiratory syndrome (MERS), a deadly coronavirus that also originated in camels and was identified in humans for the first time in 2012.

'HCoV-229E' is one of four human coronaviruses that cause common colds. While infection with the virus is generally harmless to humans, researchers say its global spread through human-to-human transmission could now be cause for concern.

Professor Christian Drosten from the University Hospital of Bonn in Germany said: "Our current study gives us a warning sign regarding the risk of a MERS pandemic - because MERS could perhaps do what HCoV-229E did."

Led by Prof Drosten, the research team examined around 1,000 camels for coronaviruses and were surprised to find pathogens related to HCoV-229E in nearly six per cent of cases. Further analysis indicated the virus was transmitted from camels to humans.

The common cold viruses isolated from camels were also able to enter human cells through the same receptor used by HCoV-229E. However, the human immune system can protect itself against the camel viruses and further testing indicated there is no immediate risk of an epidemic in humans, as the majority of the human population has immunity.

But Prof Drosten said the MERS virus "is a strange pathogen".

"Smaller, regionally restricted outbreaks, for example in hospitals, keep occurring. Fortunately, the virus has not adapted well enough to humans, and has consequently been unable to spread globally up to now."

Based on their findings, the team say there is a need for action and they are working to develop a vaccine against MERS, which will go into clinical testing next year.

Become a member or log in to add this story to your CPD history

RCVS Knowledge appoints Veterinary Evidence editor-in-chief

News Story 1
 RCVS Knowledge has welcomed Professor Peter Cockcroft as editor-in-chief for Veterinary Evidence.

A world-renowned expert in evidence-based veterinary medicine, Prof Cockcroft will lead the strategic development and editorial quality of the open-access journal. He was previously in the role from 2017-2020.

Katie Mantell, CEO of RCVS Knowledge, said: "We are excited about the extensive knowledge of evidence-based veterinary medicine and clinical veterinary research that Peter brings, and we look forward to working with him over this next phase of the journal's development." 

Click here for more...
News Shorts
Defra to host bluetongue webinar for vets

The Department for Environment, Food and Rural Affairs (Defra) will be hosting a webinar for veterinary professional on bluetongue on Thursday, 25 April 2024.

Topics covered will include the transmission cycle, pathology and pathogenesis, clinical signs (including signs seen in recent BTV-3 cases in the Netherlands), and control and prevention.

The session, which will take place from 6pm to 7.30pm, is part of Defra's 'Plan, Prevent and Protect' webinar series, which are hosted by policy officials, epidemiologists and veterinary professionals from Defra and the Animal and Plant Health Agency. The bluetongue session will also feature insights from experts from The Pirbright Institute.

Those attending will have the opportunity to ask questions. Places on the webinar can be booked online.